HEALTH NEWS
Antidepressant drug reduced Covid-19 hospitalisation risk by one-third
A large-scale study said that treating high-risk Covid-19 patients with the antidepressant fluvoxamine may reduce the risk of prolonged hospitalisation by up to a third.
According to the authors, research could help boost low-cost protection against severe sickness or death in countries that have yet to receive adequate vaccine doses during a grossly uneven rollout.
Fluvoxamine is used to treat mental health conditions such as depression and obsessive-compulsive disorders and was selected for trial due to its anti-inflammatory properties.